ValuEngine upgraded shares of Recro Pharma (NASDAQ:REPH) from a hold rating to a buy rating in a research report report published on Wednesday.
A number of other research firms have also weighed in on REPH. Zacks Investment Research raised shares of Recro Pharma from a sell rating to a hold rating in a report on Wednesday, March 21st. Oppenheimer reissued a buy rating on shares of Recro Pharma in a report on Friday, March 23rd. CIBC assumed coverage on shares of Recro Pharma in a report on Wednesday, February 14th. They issued an outperform rating and a $19.00 target price for the company. Finally, UBS started coverage on shares of Recro Pharma in a report on Tuesday, February 13th. They issued an outperform rating for the company. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $14.21.
REPH stock opened at $11.49 on Wednesday. Recro Pharma has a fifty-two week low of $5.81 and a fifty-two week high of $12.23. The company has a quick ratio of 1.55, a current ratio of 1.75 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $224.04, a P/E ratio of -5.77 and a beta of -0.74.
In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of Recro Pharma stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $10.07, for a total transaction of $2,014,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 21.60% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in Recro Pharma by 1.4% during the fourth quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after buying an additional 13,799 shares during the period. Lyon Street Capital LLC bought a new stake in shares of Recro Pharma during the fourth quarter worth $3,362,000. Cadence Capital Management LLC lifted its position in shares of Recro Pharma by 7.8% during the fourth quarter. Cadence Capital Management LLC now owns 180,715 shares of the specialty pharmaceutical company’s stock worth $1,672,000 after purchasing an additional 13,078 shares during the last quarter. State Street Corp bought a new stake in shares of Recro Pharma during the second quarter worth $1,047,000. Finally, Renaissance Technologies LLC lifted its position in shares of Recro Pharma by 23.4% during the fourth quarter. Renaissance Technologies LLC now owns 122,000 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after purchasing an additional 23,100 shares during the last quarter. 56.84% of the stock is owned by institutional investors.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.